Quantitative benefit-risk assessment using only qualitative information on utilities.

Area of Science:

• Decision analysis
• Health economics
• Pharmacoeconomics

Background:

• Assessing drug benefits and risks relies on clinical outcome utilities, but numerical data can be unreliable or absent.
• Qualitative information on clinical outcomes is often available and widely agreed upon.

Purpose of the Study:

• To develop and test a method for incorporating qualitative utility information into quantitative benefit-risk assessment.
• To determine if conclusive results can be achieved using only qualitative relations between health states.

Main Methods:

• Utilized three published decision models (terfenadine vs. chlorpheniramine, MCV4 vaccination, alosetron) evaluated using quality-adjusted life years (QALYs).
• Identified straightforward qualitative relations among clinical outcomes within each model.
• Employed Monte Carlo simulations to combine qualitative utility distributions with existing probabilities for preference assessment.

Main Results:

• The method conclusively favored MCV4 vaccination, aligning with QALY assessments.
• Concordance with QALYs was observed for terfenadine vs. chlorpheniramine.
• An unfavorable benefit-risk balance for alosetron was identified in highly risk-averse patients, a finding not present in the original QALY analysis.

Conclusions:

• Integrating qualitative information into quantitative benefit-risk assessment can yield conclusive results.
• This approach is valuable for population and individual assessments, particularly when numerical utility data are scarce or unreliable.
• The proposed method offers a practical solution for benefit-risk assessment under resource constraints.